SO
PGNX

STRS Ohio’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

STRS Ohio’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-78,400
Closed -$577K – 1962
2017
Q3 		$577K Hold
78,400
– – ﹤0.01% 1315
2017
Q2 		$532K Buy
78,400
+4,500
+6% +$33.2K ﹤0.01% 1319
2017
Q1 		$697K Sell
73,900
-11,900
-14% -$119K ﹤0.01% 1099
2016
Q4 		$741K Buy
85,800
+54,600
+175% +$404K ﹤0.01% 1053
2016
Q3 		$197K Sell
31,200
-1,200
-4% -$7.25K ﹤0.01% 1553
2016
Q2 		$136K Sell
32,400
-75,300
-70% -$364K ﹤0.01% 1641
2016
Q1 		$469K Hold
107,700
– – ﹤0.01% 1284
2015
Q4 		$660K Buy
107,700
+7,753
+8% +$50.8K ﹤0.01% 1101
2015
Q3 		$571K Buy
+99,947
New +$767K ﹤0.01% 1215

Other funds holding PGNX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
PFC
Phocas Financial Corp Alameda, California $637M AUM 39.08% 1-Year Est. Return

STRS Ohio's PGNX Position: Q4 2017 in Review

STRS Ohio sold out of Progenics Pharmaceuticals Inc (PGNX) in Q4 2017, closing a stake of 78,400 shares — an estimated $577K sold.

STRS Ohio first reported a position in PGNX in Q3 2015 and held it in 9 quarters. The position peaked at $741K in Q4 2016. 153 funds tracked by Wall St. Rank hold PGNX as of Q4 2017.

  • STRS Ohio reported no remaining Progenics Pharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
  • STRS Ohio sold 78,400 Progenics Pharmaceuticals Inc shares in Q4 2017, an estimated $577K.
  • STRS Ohio first reported a position in Progenics Pharmaceuticals Inc in Q3 2015 and held it in 9 quarters.
  • STRS Ohio's Progenics Pharmaceuticals Inc position peaked at $741K in Q4 2016.
  • 153 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q4 2017.

Based on STRS Ohio's 13F filing for Q4 2017, filed 23 Jan 2018.